Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, Bioavailability, and Food Effect of JNJ-61393215 in Healthy Subjects
NCT03649997Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of rocavorexant in major depressive disorder (MDD) and panic disorder (5 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Analyte Concentration at 72 hours, Time to Reach Maximum Observed Analyte Concentration at 48 hours and 4 more. Started Aug 2018; status: completed.
02
Drugs
rocavorexant
03
Conditions
major depressive disorder (MDD)panic disorder
Beyond the preview
Go deeper on NCT03649997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03649997.